Aditum Bio
Venture capitalOakland · Series A–Series B · 4 people tracked
Also known as ADITUM BIO MANAGEMENT COMPANY, LLC
Investment thesis
Aditum Bio pursues an alternative, patient-driven model of drug development aimed at identifying promising, clinic-ready therapies for underserved patient populations in areas such as obesity, depression, substance abuse, renal disease, and infectious diseases. Many drug candidates go undeveloped due to strategic decisions and high clinical trial costs, and the firm seeks to fill that gap. Using in-house R&D domain experts as the foundation of an agile operating model, it accelerates the formation and ramp-up of portfolio companies, augmenting dedicated leadership teams with medical and scientific experts. The firm leverages technology and partnerships to execute clinical trials efficiently, advancing acquired drug candidates into Phase 2 more quickly and at lower cost.
Source: firm website, verified Aug 25, 2026.
Team · 4 people
from the firm's website & public directories
What they invest in
from 6 of 7 portfolio companiesBiotech ×6Medical Devices ×5Digital Health ×3Healthtech ×2
HQs:United States×5
Investments · 7 tracked
founders shown can be your intro pathBy year:2025 · 12021 · 12 dated
Co-investorsKleiner PerkinsMassChallenge MexicoMicron Ventures
Coastline Bio is a biopharmaceutical company developing novel medicines for immunological skin diseases, with an initial focus on atopic dermatitis.
BiotechHealthtechMedical DevicesOakland, US
BiotechOakland, US
Christian Klee(Executive Officer)Paul Johnson(Executive Officer, Director)Ricardo Dolmetsch(Executive Officer, Director)Julie Shah(Executive Officer)
Board seatJoseph JimenezJoshua Gertsman· per SEC Form D · $77M raise · filed Nov 2025
Co-investors8VC
Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections.
BiotechDigital HealthMedical DevicesOakland, US
Donald Ganem(Executive Officer, Director)Benjamine Liu(Director)Ilan Zipkin(Director)
Board seatJoseph Jimenez· per SEC Form D
Co-investorsPMV
Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source.
BiotechDigital HealthMedical DevicesOakland, US
Kalexo Bio develops dual-targeting siRNA therapeutics for cardiovascular disease, with a focus on lipid management and atherosclerotic disease prevention.
BiotechDigital HealthMedical Devices
Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion.
BiotechHealthtechMedical DevicesLexington, US
Samantha Truex(Chief Executive Officer)in
Co-investorsGV (Google Ventures)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioEli LillyNYSE: LLY
Portfolio news
latest coverage across their companiesFrequently asked questions
- How many investments has Aditum Bio made?
- Aditum Bio has 6 tracked investments.
- What stage does Aditum Bio invest at?
- Aditum Bio invests at the Series A, Series B stages.
- What sectors does Aditum Bio focus on?
- Aditum Bio focuses on AI & Machine Learning, Biotech.
- Where is Aditum Bio located?
- Aditum Bio is headquartered in Oakland, US.
- Who does Aditum Bio co-invest with?
- Aditum Bio most often shares deals with GV (Google Ventures), Kleiner Perkins, MassChallenge Mexico, among 5 tracked co-investors.
Images
Co-investors · 1
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Firms observed investing alongside Aditum Bio, from public investor directories. Shared companies are the overlap with Aditum Bio's recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.